16 – 30 of 38
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
A targeted mass spectrometry strategy for developing proteomic biomarkers : a case study of epithelial ovarian cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Claudin-4 Expression is Associated with Survival in Ovarian Cancer but Not with Chemotherapy Response
(
- Contribution to journal › Article
-
Mark
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial
(
- Contribution to journal › Article
-
Mark
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
(
- Contribution to journal › Article
-
Mark
Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
(
- Contribution to journal › Article
- 2017
-
Mark
Involvement of chromatin remodeling genes and the Rho GTPases RhoB and CDC42 in ovarian clear cell carcinoma
(
- Contribution to journal › Article
-
Mark
Claudin-4 expression is associated with progression free survival in ovarian cancer, but not with chemotherapy response
(
- Contribution to journal › Article
- 2016
-
Mark
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
(
- Contribution to journal › Article
- 2015
-
Mark
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.
(
- Contribution to journal › Article
-
Mark
Ovarialcancer är på många sätt en heterogen sjukdom
(
- Contribution to journal › Article
- 2014
-
Mark
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
(
- Contribution to journal › Article
-
Mark
Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
(
- Contribution to journal › Article
-
Mark
Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome.
(
- Contribution to journal › Article
- 2011
-
Mark
Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors
(
- Contribution to journal › Article
- 2010
-
Mark
Genetic profiles distinguish different types of hereditary ovarian cancer.
(
- Contribution to journal › Article